Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 5Carcinoma, Non-Small-Cell Lung 2Stomatitis 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Melanoma 1Malignant Ascites 1Lung Cancer Metastatic 1Colonic Neoplasms 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 93Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 51Doxorubicin 50atezolizumab 48trametinib 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms × regramostim × Clear all
NCT00582140 2019-11-19

Prostatic Acid Phosphatase (PAP) Vaccine in Patients With Prostate Cancer

University of Wisconsin, Madison

Phase 1 Completed
22 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡